cyclic-gmp and Mydriasis

A biochemical basis for the development of tolerance to morphine has yet to be defined. Although a number of models have been proposed, none can account for complete tolerance to this drug. Previous studies in our laboratory indicated that the development of complete tolerance to certain morphine-induced behaviors (antinociception, catalepsy and respiratory depression) is associated with changes in the activity of some form(s) of phosphodiesterase with cyclic GMP as substrate (cGMP-PDE) activity in the brain areas that mediate these behaviors (periaqueductal gray, striatum and medulla). In the present study, experiments were performed in which Cyclo(Leu-Gly), a dipeptide that inhibits the development of tolerance to morphine, was administered daily (2 mg/kg) to morphine-naive rats, coadministered with morphine or coadministered with morphine to morphine-tolerant rats and the cGMP-PDE activity was measured. The development of tolerance to the effects was inhibited or reversed by administration of cyclo(Leu-Gly) and there were corresponding changes in cGMP-PDE activity in various brain regions. Differences in cGMP hydrolysis between brain regions from morphine-tolerant animals, tolerance-inhibited animals and tolerance-reversed animals strengthens the evidence for direct involvement of cGMP-PDE(s) in tolerance phenomena.

Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Catalepsy; Corpus Striatum; Cyclic GMP; Depression, Chemical; Drug Tolerance; Hydrolysis; Male; Medulla Oblongata; Morphine; Motor Activity; Mydriasis; Neuropeptides; Nociceptors; Oculomotor Nerve; Peptides, Cyclic; Periaqueductal Gray; Rats; Rats, Inbred Strains; Respiratory System